Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Positive relationship of clinical and serologic responses to vaccinia melanoma oncolysate.

Publication ,  Journal Article
Wallack, MK; Bash, JA; Leftheriotis, E; Seigler, H; Bland, K; Wanebo, H; Balch, C; Bartolucci, AA
Published in: Arch Surg
December 1987

In this phase Ia/Ib trial, vaccinia melanoma oncolysate (VMO) is a virus-augmented melanoma cell membrane vaccine that has been shown to be safe and to stimulate the production of antimelanoma antibodies in high-risk melanoma patients treated in a surgical adjuvant setting. One patient with stage I and 38 patients with stage II melanoma were entered in the study between December 1984 and October 1985, with a mean follow-up of approximately 17 months. Each patient received a smallpox booster injection followed one week later by the first of 13 weekly intradermal injections of 2.0 mg of VMO. At the end of 13 weeks, injections were given every other week for 12 months or until recurrence. Clinical results show that 25 of the 39 patients had no evidence of disease as of December 1986. Moreover and more importantly, statistical comparison of patients in this study with 39 matched controls shows a significant increase in disease-free survival for the patients treated with VMO. Serum obtained prior to treatment and at three-month intervals during treatment was tested in a Staphylococcus protein A rosette assay for reactivity with melanoma cell lines. All pretreatment samples (39/39) were negative, and 64% became positive by 12 months after appropriate dosage escalations. Moreover, enzyme-linked immunosorbent assay showed a positive correlation between anti-melanoma IgG antibody titer and disease-free survival.

Duke Scholars

Published In

Arch Surg

DOI

ISSN

0004-0010

Publication Date

December 1987

Volume

122

Issue

12

Start / End Page

1460 / 1463

Location

United States

Related Subject Headings

  • Viral Vaccines
  • Vaccinia virus
  • Time Factors
  • Surgery
  • Smallpox Vaccine
  • Neoplasm Staging
  • Melanoma
  • Male
  • Immunization, Secondary
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wallack, M. K., Bash, J. A., Leftheriotis, E., Seigler, H., Bland, K., Wanebo, H., … Bartolucci, A. A. (1987). Positive relationship of clinical and serologic responses to vaccinia melanoma oncolysate. Arch Surg, 122(12), 1460–1463. https://doi.org/10.1001/archsurg.1987.01400240108020
Wallack, M. K., J. A. Bash, E. Leftheriotis, H. Seigler, K. Bland, H. Wanebo, C. Balch, and A. A. Bartolucci. “Positive relationship of clinical and serologic responses to vaccinia melanoma oncolysate.Arch Surg 122, no. 12 (December 1987): 1460–63. https://doi.org/10.1001/archsurg.1987.01400240108020.
Wallack MK, Bash JA, Leftheriotis E, Seigler H, Bland K, Wanebo H, et al. Positive relationship of clinical and serologic responses to vaccinia melanoma oncolysate. Arch Surg. 1987 Dec;122(12):1460–3.
Wallack, M. K., et al. “Positive relationship of clinical and serologic responses to vaccinia melanoma oncolysate.Arch Surg, vol. 122, no. 12, Dec. 1987, pp. 1460–63. Pubmed, doi:10.1001/archsurg.1987.01400240108020.
Wallack MK, Bash JA, Leftheriotis E, Seigler H, Bland K, Wanebo H, Balch C, Bartolucci AA. Positive relationship of clinical and serologic responses to vaccinia melanoma oncolysate. Arch Surg. 1987 Dec;122(12):1460–1463.

Published In

Arch Surg

DOI

ISSN

0004-0010

Publication Date

December 1987

Volume

122

Issue

12

Start / End Page

1460 / 1463

Location

United States

Related Subject Headings

  • Viral Vaccines
  • Vaccinia virus
  • Time Factors
  • Surgery
  • Smallpox Vaccine
  • Neoplasm Staging
  • Melanoma
  • Male
  • Immunization, Secondary
  • Humans